Sugi Predict

Sugi Predict / Compounds / SCHEMBL1021783

SCHEMBL1021783

SCHEMBL1021783

CCOC(=O)c1cc(=O)c2ccc(O)cc2o1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1B1 P15121 4/20 1.00
▸ SLC2A1 P11166 1/20 0.63
▸ MAOB P27338 3/20 0.62
▸ KDM4E B2RXH2 3/20 0.57
▸ ALDH1A1 P00352 3/20 0.57
▸ HPGD P15428 2/20 0.57
▸ CASP1 P29466 2/20 0.57
▸ CASP7 P55210 2/20 0.57
▸ HSD17B10 Q99714 2/20 0.57
▸ TSHR P16473 2/20 0.57
▸ MEN1 O00255 1/20 0.57
▸ MAPT P10636 1/20 0.57
▸ ALOX15 P16050 1/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ JAK2 O60674 1/20 0.56
▸ JAK1 P23458 1/20 0.56
▸ TYK2 P29597 1/20 0.56
▸ JAK3 P52333 1/20 0.56
▸ MIF P14174 1/20 0.53
▸ PFKFB3 Q16875 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29495537 1.00 AKR1B1 (1.00) AKR1B1SLC2A1MAOBKDM4EALDH1A1
SCHEMBL115442 0.89 AKR1B1 (0.80) AKR1B1SLC2A1MAOBALDH1A1HPGD
SCHEMBL29495358 0.89 AKR1B1 (0.80) AKR1B1SLC2A1MAOBALDH1A1HPGD
SCHEMBL30989208 0.88 AKR1B1 (0.77) AKR1B1SLC2A1MAOBKDM4EALDH1A1
SCHEMBL8827849 0.87 AKR1B1 (0.78) AKR1B1SLC2A1MAOBKDM4EALDH1A1
SCHEMBL8117451 0.87 AKR1B1 (0.78) AKR1B1SLC2A1MAOBKDM4EMEN1
SCHEMBL4250015 0.86 AKR1B1 (0.76) AKR1B1SLC2A1MAOBKDM4EALDH1A1
SCHEMBL6332284 0.85 AKR1B1 (0.74) AKR1B1SLC2A1MAOBKDM4EALDH1A1
SCHEMBL6339410 0.85 MAOB (0.81) AKR1B1SLC2A1MAOBKDM4EALDH1A1
SCHEMBL8119217 0.84 AKR1B1 (0.74) AKR1B1MAOBKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240392220-A1 BRANDY REPLICAS AVA FOOD LABS, INC. 2024-11-28 — — US disclosed
CN-118339274-A Brandy replica 艾娃食品实验室股份有限公司 2024-07-12 — — CN disclosed
US-20240051931-A1 HDAC INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2024-02-15 — — US disclosed
US-11891365-B2 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors VALO HEALTH, INC. (US) 2024-02-06 — — US disclosed
US-20240018133-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2024-01-18 — — US disclosed
US-20230270663-A1 FORMULATION FOR THE TREATMENT OF FINE LINES AND WRINKLES AND USES THEREOF BAIN CAPITAL CREDIT, LP, AS COLLATERAL AGENT 2023-08-31 — — US disclosed
US-20230270663-A1 FORMULATION FOR THE TREATMENT OF FINE LINES AND WRINKLES AND USES THEREOF BAIN CAPITAL CREDIT, LP, AS COLLATERAL AGENT 2023-08-31 — — US disclosed
CN-109641864-B Anti-infective agents 邓迪大学 2023-04-04 — — CN disclosed
US-20220363651-A1 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS Valo Health, LLC 2022-11-17 — — US disclosed
US-11485720-B2 Anti-infective agents UNIVERSITY OF DUNDEE (GB) 2022-11-01 — — US disclosed
US-4788214-A ANTIALLERGENS HOFFMAN-LA ROCHE INC. (US) 1988-11-29 — — US disclosed
US-4785017-A ANTIALLERGENS HOFFMANN-LA ROCHE INC. (US) 1988-11-15 — — US disclosed
US-4761425-A ANTIASTHMATICS; ANTIALLERGENS, ANTIINFLAMMATORY AGENTS MERCK FROSST CANADA, INC. (CA) 1988-08-02 — — US disclosed
EP-0129906-B1 PHENOXYALKOXY-3,4-DIHYDRO-2H-1-BENZOPYRAN DERIVATIVES F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1988-06-08 — — EP disclosed
EP-0235463-A2 N-substituted-arylalkyl and arylalkylene piperidines as cardiovascular antihistaminic and antisecretory agents A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) 1987-09-09 — — EP disclosed
US-4609744-A 4-oxo-benzopyran carboxylic acids MERCK FROSST CANADA INC. (CA) 1986-09-02 — — US disclosed
EP-0147217-A2 Leukotriene antagonists MERCK FROSST CANADA INC. (CA) 1985-07-03 — — EP disclosed
EP-0123543-A1 Leukotriene antagonists, their production and use and compositions containing them MERCK FROSST CANADA INC. (CA) 1984-10-31 — — EP disclosed
US-4282247-A ANTIANAPHYLACTIC, ANTIALLERGENIC CM INDUSTRIES (FR) 1981-08-04 — — US disclosed
US-4133889-A ANAPHYLAXIS ANTAGONISTS FISONS, LTD. (GB) 1979-01-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11485720-B2 Anti-infective agents C1R, RRS1, ARG1 AKR1B1 2303/4885SLC2A1 4796/4885MAOB 2696/4885
US-11891365-B2 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors HDAC1, HDAC4, HDAC2 AKR1B1 2024/4885SLC2A1 3806/4885MAOB 615/4885
US-20240018133-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 AKR1B1 1312/4885SLC2A1 822/4885MAOB 3069/4885
US-20240051931-A1 HDAC INHIBITORS HDAC8, HDAC1, HDAC2 AKR1B1 2293/4885SLC2A1 3751/4885MAOB 1930/4885
US-20230270663-A1 FORMULATION FOR THE TREATMENT OF FINE LINES AND WRINKLES AND USES THEREOF CUTA, RXRA, RARA AKR1B1 3575/4885SLC2A1 1716/4885MAOB 1249/4885
US-20220363651-A1 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS HDAC1, HDAC4, HDAC2 AKR1B1 2024/4885SLC2A1 3806/4885MAOB 615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.